Huanova raises tens of millions in Series A+ funding to lead global 'self-healing' biomaterials tech

Shenzhen Huanova Biotechnology Co., Ltd. ("Huanova") recently announced the completion of its A+ round of financing. This round was led by Guozhong Capital, with participation from Xinchantou (Shenzhen) Investment, and Shenzhen Synthetic Capital acted as the exclusive financial advisor for this round. The funds raised will primarily be used to expand the company's product pipeline based on its self-developed self-healing supramolecular technology platform and to upgrade the production capacity of its core products.

Huanova, as a representative enterprise in China's self-healing new materials technology sector, has innovatively applied its "Self-healing Supramolecular" technology to develop injectable and moldable fluid-type implantable consumables. Its first Class III medical device product, "Colloidose® Absorbable Hemostatic Fluid Gelatin," obtained medical device registration certification (National Device Approval No. 20243142042) from China's National Medical Products Administration in October 2024.

Compared to the traditional "micron"-scale granulation technology used in conventional hemostatic fluid products, Huanova's proprietary "Self-healing Supramolecular" technical approach not only maintains the minimally invasive injection characteristics but also significantly enhances the mechanical properties of the hemostatic fluid. This innovation enables more stable wound hemostasis efficacy and demonstrates promising clinical application prospects.

Amid the current cooling capital market environment and increasingly cautious investment climate, Huanova's successful financing round can be attributed to its distinctive, innovative, and leading technological foundation, coupled with excellent clinical data. With capital support, the company is poised to rapidly advance the commercialization of this product and accelerate the development of its subsequent pipeline reserves.

Huanova's Self-developed Self-healing Gel Materials

Founded in December 2017, Huanova features a technical team with over 20 years of industry experience, deeply engaged in biomedical materials and regenerative medicine research. The team has published more than 100 scientific papers in top-tier academic journals including Nature Materials, Advanced Materials, and Biomaterials, and holds over 40 authorized invention patents globally.

With more than 80% of the R&D team holding master's or doctoral degrees, the company possesses profound technical expertise in medicine, materials science, and regenerative medicine, complemented by substantial industrial experience and keen business acumen.

Huanova's unique self-healing supramolecular biomedical material technology system endows biomaterials with a series of characteristics including minimal invasiveness, precision, adaptability, and functionality, aligning with the urgent clinical demands for minimally invasive and precise surgical techniques. The company's current product pipeline is strategically focused on two major clinical need areas: perioperative trauma management and tissue regenerative medicine, with an emphasis on developing innovative medical devices and novel regenerative material technologies. Its pipeline under development includes over ten types of biomedical consumables such as advanced hemostatic materials, tissue adhesives, tissue engineering scaffolds, medical aesthetic implantable gels, and stem cell carriers, addressing a market potential spanning billions of dollars.

Huanova has secured three medical device registrations, one filing for an innovative pharmaceutical excipient, and one for a new cosmetic ingredient in China. To date, the company has established in-depth collaborations with over 800 tertiary hospitals across the country, facilitating the rapid commercialization of its supramolecular technology-based "Absorbable Fluid Gelatin."